Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

USB Upgrades Esperion to 'Outperform'

USB Bancorp upgraded Esperion Therapeutics (ESPR) to outperform.

Analyst Mark Schoenenbaum says the success of ETC-216, a drug that is derived from a protein of the "good cholesterol" known as HDL, represents a major medical breakthrough: unclogging an artery in five weeks. To his knowledge, this is the first drug able to shrink coronary artery plaque in five weeks. He notes Esperion is also conducting trials on two additional HDL-based therapies.

Pfizer has first negotiation rights for ETC-216. Given the success of ETC-216, Schoenenbaum thinks Esperion can now get better economic terms for some other drugs it is currently testing. He raised his price target to $18.

blog comments powered by Disqus